Global TCR Therapy Market (2nd Edition): Distribution by Target Indication (Nasopharyngeal Carcinoma, Multiple Myeloma, Head and Neck Carcinoma, Sarcoma, Melanoma, Acute Myeloid Leukemia, Lung Cancer, Ovarian Cancer, and Merkel Cell Cancer), Target Antigen (NY-ESO-1, EBV, gp100, and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2023

  • Pages
    363

  • View Count
    8219

Example Insights

Global-TCR-based-Therapy-Market-Context-thumb Global-TCR-based-Therapy-Market-Pipeline-thumb Global-TCR-based-Therapy-Market-Landscape-thumb Global-TCR-based-Therapy-Market-Trial-Analysis-thumb
Global-TCR-based-Therapy-Market-Leaders-thumb Global-TCR-based-Therapy-Market-Manufacturers-thumb Global-TCR-based-Therapy-Market-Collaborations-thumb Global-TCR-based-Therapy-Market-Investments-thumb
Global-TCR-based-Therapy-Market-Field-thumb Global-TCR-based-Therapy-Market-Antigen-thumb    

Overview

Modified T-cell receptor therapy (TCR therapy) is an emerging class of adoptive therapy that employs genetically modified lymphocytes to target specific tumor markers. Their tumor-cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens; this enables such interventions to selectively target and eliminate tumor cells from the body of a host with negligible treatment-related side effects. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various hematological cancers and solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the TCR therapy market is likely to witness significant growth in the foreseen future.

Key Market Insights

The “Global TCR Therapy Market (2nd Edition), 2022-2035: Distribution by Target Indication (Nasopharyngeal Carcinoma, Multiple Myeloma, Head and Neck Carcinoma, Sarcoma, Melanoma, Acute Myeloid Leukemia, Lung Cancer, Ovarian Cancer, and Merkel Cell Cancer), Target Antigen (NY-ESO-1, EBV, gp100, and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of the current market landscape and future potential of TCR-based therapies. The report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. The report answers many key questions related to this domain:

Need for TCR Therapies for the Treatment of Various Types of Cancer
Modified T-cell receptor therapy (TCR therapy), an upcoming class of cell-based interventions, is a promising therapeutic modality. Similar to other T-cell based interventions (such as CAR-T cells and TILs), TCR therapies are designed to target the underlying causes (or primary mediators) of a clinical condition. Additionally, this emerging class of biologics is believed to possess the potential to cater to unmet pharmacological needs across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate. Although TCR-based immunotherapies are still considered an experimental approach, several clinical studies demonstrate the efficacy and therapeutic superiority of TCR cell products.

Current Market Landscape of TCR Therapies
Presently, more than 100 industry and non-industry players across the globe are evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders. It is worth highlighting that, in January 2022, the FDA approved the first TCR-based therapy, Kimmtrak® (Immunocore), for the treatment of adult patients with unresectable or metastatic uveal melanoma.  More than 90% of the therapy candidates that are being developed to target a wide range of disease indications are autologous in nature. Further, NY-ESO-1 and MAGE emerged as the most popular target antigens in this domain.

Rising Interest in TCR Therapies
The growing interest in this field is reflected in the notable increase in partnerships inked (close to 140 deals inked in the past decade; CAGR 23%) by several industry players and academic / research institutes. Additionally, various investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion across 140 instances, since 2007. Further, in the last 10 years, close to 110 clinical trials have been registered across different geographies for the evaluation of TCR therapies. Mostly driven by the need for effective treatment options for cancer, the TCR therapy pipeline is expected to steadily grow over the coming years. Moreover, clinical success is likely to draw in investments that are likely to support the ongoing and anticipated therapy development initiatives.

Market Size of the TCR Therapy Market
With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 51% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by nasopharyngeal carcinoma, multiple myeloma, and head and neck carcinoma. Additionally, more than 80% of the market is anticipated to be captured by players based in Europe and Asia-Pacific in 2035. Overall, we are led to believe that the global TCR  therapy market is poised to witness significant growth in the foreseen future.

Who are the Key Players in the TCR Therapy Market
Examples of key players engaged in this domain (which have also been captured in this report) include Adaptimmune Therapeutics, Alaunos Therapeutics, blubird bio, Bristol Myers Squibb, Cellular Biomedicine Group, China Immunotech, Gilead Sciences, GlaxoSmithKline, Immatics
Immunocore, Intellia Therapeutics, Lion TCR, Takara Bio, TCRCure Biopharma, and Zelluna Immunotherapy. 

Scope of the Report
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments as defined in the below table:

Key Report Attributes Details

Forecast Period

2022 – 2035

Target Indications

Nasopharyngeal Carcinoma, Multiple Myeloma, Head and Neck Carcinoma, Sarcoma, Melanoma, Acute Myeloid Leukemia, Lung Cancer, Ovarian Cancer, Merkel Cell Cancer

Target Antigens

NY-ESO-1, EBV, gp100

Key Players

GlaxoSmithKline, China Immunotech, Xinqiao Hospital of Chongqing, TCRCure Biopharma, Adaptimmune Therapeutics, Immunocore, Intellia Therapeutics, Takara Bio, bluebird bio

Key Geographical Regions

North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa (MENA), Rest of the World

Key Companies Profiled

Adaptimmune Therapeutics, Alaunos Therapeutics, Bristol Myers Squibb, Cellular Biomedicine, Gilead Biosciences, GlaxoSmithKline, Immatics, Immunocore, Lion TCR, Takara Bio, Zelluna Immunotherapy

Customization Scope 15% Free Customization Option (equivalent to 5 analyst working days)
Powerpoint Presentation Complimentary
Excel Data Packs Complimentary: Market Landscape Analysis, Clinical Trial Analysis, KOL Analysis, Partnership and Collaboration Analysis, Funding and Investment Analysis, Patent Analysis, Market Forecast and Opportunity Analysis

The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of global TCR-based therapies market and its likely evolution in the mid-long term.
  • A general overview of TCR-based therapies in comparison to conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, and key attributes in development of TCR-based therapies
  • A detailed assessment of the overall market landscape of TCR-based therapies, based on several relevant parameters, such as type of developer (industry and non-industry), phase of development (approved, phase II, phase I / II, phase I, and preclinical), therapeutic area (hematological cancer, solid tumor, and undisclosed), key target indication (lung cancer, melanoma, hepatocellular carcinoma, cervical cancer, ovarian cancer, sarcoma, breast cancer, gastric cancer, multiple myeloma, pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, nasopharyngeal carcinoma, and others), key target antigen (NY-ESO-1, MAGE, HBV, PRAME, KRAS, EBV, HPV, Neoantigen, LAGE-1a, Meso, HLA, and others), source of T-cells (autologous / allogeneic), route of administration (intravenous and intratumoral), dosing frequency (single dose, multiple dose, and split dose), target patient segment (children, adults, and elderly patients), type of therapy (monotherapy and combination therapy) and most active players (in terms of number of TCR-based therapies). Further, the chapter also provides developer landscape of industry and non-industry players engaged in this domain. 
  • A detailed analysis of popular target antigens, based on the number of TCR-based therapies that are being developed for a particular type of antigen by various industry stakeholders to identify potential targets.
  • An analysis of completed, ongoing, and planned clinical studies related to TCR-based therapies, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, target patient segment, type of sponsor / collaborator, most active players (in terms of number of registered trials), key focus areas and geography.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to TCR-based therapies, considering them to be KOLs, who are actively involved in R&D of TCR-based therapies. In addition, it compares the relative expertise of KOLs based on a proprietary scoring criterion with that of a third party.
  • Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), a clinical development plan, and clinical trial results.
  • A detailed analysis of recent partnerships inked between several stakeholders engaged in this domain, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures, and others.
  • An analysis of the funding and investments that have been made into companies having proprietary TCR-based products / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing.
  • An in-depth analysis of patents related to TCR-based therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted, patent applications, and search reports), patent publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus area, type of player, leading player (in terms of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents. 
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • A n elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a TCR-based therapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that are being implemented by the developers of the approved TCR-based therapy (Kimmtrak®).
  • Elaborate profiles of the leading players in the domain of TCR-based therapies. Each company profile includes an overview of the developer and a brief description of the product portfolio specific to TCR-based therapies, the technology portfolio (if available), recent developments related to TCR-based therapies, and the manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the report was to estimate the current opportunity and the future growth potential of TCR-based therapies over the coming decade. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the period 2022-2035. The report also includes likely sales forecasts of TCR-based therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TCR-based therapies market, wherein both the current and upcoming opportunity is segmented across target indication (nasopharyngeal carcinoma, multiple myeloma, head and neck carcinoma, sarcoma, melanoma, acute myeloid leukemia, lung cancer, ovarian cancer and merkel cell cancer), target antigen (NY-ESO-1, EBV, gp100 and others), key players and key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:

  • Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
  • Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
  • Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
  • Miguel Forte (Former Chief Operating Officer, TxCell)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is the growth rate of TCR-based therapy market?
Answer: The global TCR-based therapies market is expected to grow at a compound annual growth rate of 51% from 2022-2035.

Question 2: Which region has the highest growth rate in the TCR-based Therapies market?
Answer: Asia Pacific is growing at the highest CAGR, over the period 2022- 2035.

Question 3: How many players are developing TCR-based Therapies?
Answer: More than 100 industry and non-industry players are currently evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders.

Question 4: Which target indication covers the largest TCR-based therapy market share?
Answer: Multiple myeloma, presently, captures the maximum share (43%) of TCR-based therapy market in 2022. This share is likely to decrease in the foreseen future as several promising leads are anticipated to be commercially launched over the coming decade.

Question 5: What is the partnership and collaboration trend in the TCR-based therapy domain?
Answer: Currently, R&D agreements, licensing agreements, and product development and commercialization agreements are the common type of partnerships inked by developers involved in the TCR-based therapy domain. 

Question 6: What is the current IP landscape of TCR-based therapies market?
Answer: Close to 76% of the filed patents were patent applications, while around 24% were granted patents and search reports. Of the total granted applications, close to 78% were filed in the US.

Contents

Table Of Contents

1. PREFACE
1.1. Chapter Overview
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.1.1. Active Immunotherapy
3.5.1.2. Passive Immunotherapy
3.5.2. By Type of Target
3.5.3. By Approach
3.5.3.1. Activation and Suppression Immunotherapy
3.5.4. By Product Class
3.5.4.1. Monoclonal Antibodies
3.5.4.2. Bispecific Antibodies
3.5.4.3. Cytokines
3.5.4.4. Oncolytic Virus Therapy
3.5.4.5. Therapeutic Cancer Vaccines
3.5.4.6. Cell-based Therapies
3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods
3.6.5.1. Retroviral Vectors
3.6.5.2. Lentiviral Vectors
3.6.5.3. Non-viral Transfection Methods
3.7. T-Cell Receptor (TCR)-based Cell Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of TCR
3.7.3. Development of TCR Therapy
3.7.4. Differences between CAR-T and TCR-based Therapies
3.8. Concluding Remarks

4. TCR-BASED THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. TCR-based Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indication
4.2.6. Analysis by Key Target Antigen
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Phase of Development and Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Analysis by Phase of Development and Type of Therapy
4.2.14. Most Active Industry Players: Analysis by Number of TCR-based Therapies
4.2.15. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies

4.3. TCR-based Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. POPULAR TARGET ANTIGEN ANALYSIS
5.1. Chapter Overview
5.2. Competitive Analysis: Popular Target Antigens of TCR-based Therapies
5.2.1. Popular Targets Related to Hematological Malignancies
5.2.2. Popular Targets Related to Solid Tumors

6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. TCR-based Therapies: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.3. Analysis by Trial Status
6.3.4. Analysis by Trial Registration Year and Trial Status
6.3.5. Analysis by Trial Phase
6.3.6. Analysis of Enrolled Patient Population by Trial Phase
6.3.7. Analysis by Target Patient Segment
6.3.8. Analysis by Type of Sponsor / Collaborator
6.3.9. Analysis by Study Design
6.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
6.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
6.3.12. Word Cloud Representation Analysis: Emerging Focus Areas
6.3.13. Analysis of Clinical Trials by Geography
6.3.14. Analysis of Enrolled Patient Population by Geography

7. KEY OPINION LEADERS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. TCR-based Therapies: Key Opinion Leaders
7.4.1. Analysis by Type of Organization
7.4.2. Analysis by Affiliated Organization
7.4.3. Analysis by Qualification
7.4.4. Analysis by Geographical Location of KOLs
7.4.5. KOL Activeness versus KOL Strength
7.4.6. Most Prominent KOLs: Analysis by RA score
7.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

8. TCR-BASED THERAPY PROFILES
8.1. Chapter Overview
8.2. Kimmtrak® / IMCgp100 / Tebentafusp (Immunocore)
8.2.1. Therapy Overview
8.2.2. Clinical Trial Information
8.2.3. Clinical Trial Endpoints
8.2.4. Clinical Trial Results
8.2.5. Estimated Sales Revenues

8.3. GSK3377794 / NY-ESO-1C259 T-cells / Letetresgene Autoleucel (GlaxoSmithKline)
8.3.1. Therapy Overview
8.3.2. Clinical Trial Information
8.3.3. Clinical Trial Endpoints
8.3.4. Clinical Trial Results
8.3.5. Estimated Sales Revenues

8.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
8.4.1. Therapy Overview
8.4.2. Clinical Trial Information
8.4.3. Clinical Trial Endpoints
8.4.4. Clinical Trial Results
8.4.5. Estimated Sales Revenues

8.5. JTCR016 (Juno Therapeutics)
8.5.1. Therapy Overview
8.5.2. Clinical Trial Information
8.5.3. Clinical Trial Endpoints

8.6. TBI-1301 (Takara Bio)
8.6.1. Therapy Overview
8.6.2. Clinical Trial Information
8.6.3. Clinical Trial Endpoints
8.6.4. Clinical Trial Results
8.6.5. Estimated Sales Revenues

8.7. MDG1011 (Medigene)
8.7.1. Therapy Overview
8.7.2. Clinical Trial Information
8.7.3. Clinical Trial Endpoints
8.7.4. Clinical Trial Results

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. TCR-based Therapies: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partnership
9.3.4. Analysis by Type of Partner
9.3.5. Most Popular Products: Analysis by Number of Partnerships
9.3.6. Most Active Industry Players: Analysis by Number of Partnerships
9.3.7. Most Active Non-Industry Players: Analysis by Number of Partnerships

9.3.8. Analysis by Geography
9.3.8.1. Intercontinental and Intracontinental Deals
9.3.8.2. International and Local Deals

10. FUNDING AND INVESTMENT ANALYSIS
10.1. Chapter Overview
10.2. Types of Funding
10.3. TCR-based Therapies: Funding and Investment Analysis
10.3.1. Analysis of Instances by Year
10.3.2. Analysis of Amount Invested by Year
10.3.3. Analysis by Type of Funding
10.3.4. Analysis by Type of Investor
10.3.5. Most Active Players: Analysis by Number of Instances
10.3.6. Most Active Investors: Analysis by Amount Invested
10.3.7. Analysis of Amount Invested by Geography
10.3.8. Most Active Investors: Analysis by Number of Funding Instances

11. PATENT ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. TCR-based Therapies: Patent Analysis
11.3.1. Analysis by Patent Publication Year
11.3.2. Analysis By Patent Application Year
11.3.3. Analysis by Geography
11.3.4. Analysis by Type of Player
11.3.5. Analysis by CPC Symbols
11.3.6. Analysis by Key Focus Area
11.3.7. Leading Player: Analysis by Number of Patents
11.3.8. TCR-based Therapies: Patent Benchmarking
11.3.9. Analysis By Patent Characteristics
11.3.10. TCR-based Cell Therapies: Patent Valuation

12. CASE STUDY: CELL THERAPY MANUFACTURING
12.1. Chapter Overview
12.2. Overview of Cell Therapy Manufacturing
12.3. Cell Therapy Manufacturing Models
12.3.1. Centralized Manufacturing Model
12.3.2. Decentralized Manufacturing Model
12.4. Scalability of Cell Therapy Manufacturing Processes
12.4.1. Scale-Up
12.4.2. Scale-Out
12.5. Types of Cell Therapy Manufacturers
12.6. Key Challenges Related to Manufacturing of Cell Therapies
12.7. Important Factors for Cell Therapy Manufacturing
12.7.1. Characterization
12.7.2. Cost of Goods
12.8. Automation of Cell Therapy Manufacturing Processes
12.9. Cell Therapy Manufacturing Supply Chain
12.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
12.11. Regulatory Landscape
12.12. Future Perspectives

13. COST PRICE ANALYSIS
13.1. Chapter Overview
13.2. Factors Contributing to the High Price of Cell / Gene Therapies
13.3. Pricing Models for T-Cell Immunotherapies
13.3.1. Based on Associated Costs
13.3.2. Based on Availability of Competing Products
13.3.3. Based on Patient Segment
13.3.4. Based on Opinions of Industry Experts
13.4. Reimbursement related Considerations for T-cell Immunotherapies
13.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T Therapies

14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Key Assumptions and Forecast Methodology

14.4. Global TCR-based Therapies Market, 2022-2035
14.4.1. TCR-based Therapies Market: Analysis by Target Indication
14.4.2. TCR-based Therapies Market: Analysis by Target Antigen
14.4.3. TCR-based Therapies Market: Analysis by Key Players
14.4.4. TCR-based Therapies Market: Distribution by Geography

14.4.5. Product Wise Sales Forecast
14.4.5.1. Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore)
14.4.5.1.1. Sales Forecast (USD Million)
14.4.5.1.2. Net Present Value (USD Million)
14.4.5.1.3. Value Creation Analysis

14.4.5.2. GSK3377794 (GlaxoSmithKline)
14.4.5.2.1. Sales Forecast (USD Million)
14.4.5.2.2. Net Present Value (USD Million)
14.4.5.2.3. Value Creation Analysis

14.4.5.3. YT-E001 (China Immunotech)
14.4.5.3.1. Sales Forecast (USD Million)
14.4.5.3.2. Net Present Value (USD Million)
14.4.5.3.3. Value Creation Analysis

14.4.5.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
14.4.5.4.1. Sales Forecast (USD Million)
14.4.5.4.2. Net Present Value (USD Million)
14.4.5.4.3. Value Creation Analysis

14.4.5.5. EBV-specific TCR-T cell with Anti-PD1 Aauto-secreted Element (TCRCure Biopharma)
14.4.5.5.1. Sales Forecast (USD Million)
14.4.5.5.2. Net Present Value (USD Million)
14.4.5.5.3. Value Creation Analysis

14.4.5.6. NTLA-5001 (Intellia Therapeutics)
14.4.5.6.1. Sales Forecast (USD Million)
14.4.5.6.2. Net Present Value (USD Million)
14.4.5.6.3. Value Creation Analysis

14.4.5.7. TBI-1301 (Takara Bio)
14.4.5.7.1. Sales Forecast (USD Million)
14.4.5.7.2. Net Present Value (USD Million)
14.4.5.7.3. Value Creation Analysis

14.4.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
14.4.5.8.1. Sales Forecast (USD Million)
14.4.5.8.2. Net Present Value (USD Million)
14.4.5.8.3. Value Creation Analysis
14.4.5.9. FH-MCVA2TCR (TCRCure Biopharma)
14.4.5.9.1. Sales Forecast (USD Million)
14.4.5.9.2. Net Present Value (USD Million)
14.4.5.9.3. Value Creation Analysis

15. PROMOTIONAL ANALYSIS
15.1. Chapter Overview
15.2. Channels Used for Promotional Campaigns
15.3. Kimmtrak: Promotional Analysis
15.3.1. Drug Overview
15.3.2. Product Website Analysis
15.3.2.1. Message for Healthcare Professionals
15.3.2.2. Message for Patients
15.3.2.3. Informative Downloads
15.3.3. Patient Support Services

16. COMPANY PROFILES
16.1. Chapter Overview
16.2. Adaptimmune Therapeutics
16.3. Alaunos Therapeutics
16.4. Company Profiles
16.5. Bristol Myers Squibb
16.6. Cellular Biomedicine Group
16.7. Gilead Sciences
16.8. Cellular Biomedicine Group
16.9. GlaxoSmithKline
16.10. Immatics
16.11. Immunocore
16.12. Lion TCR
16.13. Takara Bio
16.14. Zelluna immunotherapy

17. CONCLUDING REMARKS

18. EXECUTIVE INSIGHTS
18.1. Chapter Overview
18.2. Celyad
18.2.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology
18.3. Kite Pharma
18.3.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs
18.4. Lion TCR
18.4.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer
18.5. TxCell
18.5.1. Interview Transcript: Miguel Forte, Chief Operating Officer

19. APPENDIX 1: TABULATED DATA

20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1  Executive Summary: Overall Market Landscape
Figure 2.2  Executive Summary: Clinical Trial Analysis
Figure 2.3  Executive Summary: Partnerships and Collaborations
Figure 2.4  Executive Summary: Funding and Investment Analysis
Figure 2.5  Executive Summary: Patent Analysis
Figure 2.6  Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1  Pillars of Cancer Therapy
Figure 3.2  Differences between Active and Passive Immunotherapies
Figure 3.3  Differences between Specific and Non-Specific Immunotherapies
Figure 3.4  Strategies Employed for the Redirection of T-Cells
Figure 3.5  T-Cell Manufacturing: General Procedure
Figure 3.6  TCR-based Therapies: Development Process
Figure 4.1  TCR-based Therapies: Distribution by Type of Developer
Figure 4.2  TCR-based Therapies: Distribution by Phase of Development
Figure 4.3  TCR-based Therapies: Distribution by Therapeutic Area
Figure 4.4  TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5  TCR-based Therapies: Distribution by Key Target Indications
Figure 4.6  TCR-based Therapies: Distribution by Key Target Antigens
Figure 4.7  TCR-based Therapies: Distribution by Source of T-Cells
Figure 4.8  TCR-based Therapies: Distribution by Phase of Development and Source of T-Cells
Figure 4.9  TCR-based Therapies: Distribution by Route of Administration
Figure 4.10  TCR-based Therapies: Distribution by Dosing Frequency
Figure 4.11  TCR-based Therapies: Distribution by Target Patient Segment
Figure 4.12  TCR-based Therapies: Distribution by Type of Therapy
Figure 4.13  Most Active Industry Players: Distribution by Number of TCR-based Therapies
Figure 4.14  Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Figure 4.15  TCR-based Therapy Developers: Distribution by Year of Establishment
Figure 4.16  TCR-based Therapy Developers: Distribution by Company Size
Figure 4.17  TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18  TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 5.1  TCR-based Therapies: Popular Targets in Hematological Malignancies
Figure 5.2  TCR-based Therapies: Popular Targets in Solid Tumors
Figure 6.1  Clinical Trial Analysis: Scope and Methodology
Figure 6.2  Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2013-2022
Figure 6.3  Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
Figure 6.4  Clinical Trial Analysis: Distribution by Trial Status
Figure 6.5  Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 6.6  Clinical Trial Analysis: Distribution of Trials by Trial Phase
Figure 6.7  Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 6.8  Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 6.9  Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.10  Clinical Trial Analysis: Distribution by Study Design
Figure 6.11  Most Active Industry Players: Distribution by Number of Registered Trials
Figure 6.12  Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 6.13  Word Cloud Analysis: Emerging Focus Areas
Figure 6.14  Clinical Trial Analysis: Distribution of Trials by Geography
Figure 6.15  Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 6.16  Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 6.17  Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 7.1  KOL Analysis: Distribution by Type of Organization
Figure 7.2  KOL Analysis: Distribution by Affiliated Organization
Figure 7.3  KOL Analysis: Distribution by Qualification
Figure 7.4  KOL Analysis: Distribution by Geography
Figure 7.5  TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 7.6  Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 7.7  Most Prominent KOLs: Distribution by RA Score
Figure 7.8  Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 7.9  Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 8.1  Kimmtrak®: Estimated Sales Revenues
Figure 8.2  GSK3377794: Estimated Sales Revenues
Figure 8.3  ADP-A2M4: Estimated Sales Revenues
Figure 8.4  JTCR016: Estimated Sales Revenues
Figure 8.5  TBI-1301: Estimated Sales Revenues
Figure 8.6  MDG1011: Estimated Sales Revenues 
Figure 9.1  Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 9.2  Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Figure 9.4  Partnerships and Collaborations: Distribution by Year and Type of Partnership, Pre-2015-2022
Figure 9.5  Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.6  Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Figure 9.7  Most Popular Products: Distribution by Number of Partnerships
Figure 9.8  Most Active Industry Players: Distribution by Number of Partnerships
Figure 9.9 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 9.10  Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.11  Partnerships and Collaborations: International and Local Deals
Figure 10.1  Funding and Investment Analysis: Cumulative Year-wise Distribution of Instances, Pre-2018-2022
Figure 10.2  Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, Pre-2018-2022 (USD Million)
Figure 10.3  Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 10.4  Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 10.5  Funding and Investment Analysis: Distribution by Type of Investor
Figure 10.6  Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 10.7  Most Active Players: Distribution by Number of Instances
Figure 10.8  Most Active Players: Distribution by Amount Invested (USD Million)
Figure 10.9  Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 11.1  Patent Analysis: Distribution by Type of Patent
Figure 11.2  Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 11.3  Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 11.4  Patent Analysis: Cumulative Year-wise Distribution of Granted Patents
Figure 11.5  Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Figure 11.6  Patent Analysis: Year-wise Distribution of Filed Patent Applications and Granted Patents 
Figure 11.7  Patent Analysis: Distribution by Geography
Figure 11.8  Patent Analysis: Distribution by Type of Player
Figure 11.9  Patent Analysis: Distribution by CPC Symbols
Figure 11.10 Patent Analysis: Key Focus Area
Figure 11.11 Leading Industry Players: Distribution by Number of Patents
Figure 11.12  Leading Non-Industry Players: Distribution by Number of Patents
Figure 11.13  Leading Patent Assignees: Distribution by Number of Patents
Figure 11.14  Leading Players: Benchmarking by Patent Characteristics (CPC Symbols) 
Figure 11.15  Patent Analysis: Distribution by Patent Age
Figure 11.14  TCR-based Cell Therapies: Patent Valuation Analysis
Figure 12.1  Steps for Manufacturing Cell Therapies
Figure 12.2  Centralized Manufacturing: Process Model
Figure 12.3  Decentralized Manufacturing: Process Model
Figure 12.4  Cell Therapy Manufacturing: Types of Manufacturers
Figure 12.5  Cell Therapy: Challenges and Drivers
Figure 12.6  Cell Therapies: Potency as Critical Quality Attribute
Figure 12.7  Cell Therapy Manufacturing: Supply Chain Model
Figure 12.8  Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 13.1  Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 14.1  Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Figure 14.2  TCR-based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 14.3  TCR-based Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 14.4  TCR-based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 14.5  TCR-based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 14.6  Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales Forecast, till 2035 (USD Million)
Figure 14.7  GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Figure 14.8  YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Figure 14.9  ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.10  EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 14.11  NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 14.12  TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Figure 14.13  LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, till 2035 (USD Million) 
Figure 15.1  Channels Used for Promotional Campaigns
Figure 15.2  Product Website Analysis: Kimmtrak®, Messages for Healthcare Professional
Figure 15.3  Product Website Analysis: Kimmtrak®, Messages for Patients
Figure 15.4  Product Website Analysis: Kimmtrak®, Kimmtrak Connect
Figure 17.1  Concluding Remarks: Market Landscape
Figure 17.2  Concluding Remarks: Clinical Trial Analysis
Figure 17.3  Concluding Remarks: Key Opinion Leaders
Figure 17.4  Concluding Remarks: Partnerships & Collaborations
Figure 17.5  Concluding Remarks: Funding and Investment Analysis
Figure 17.6  Concluding Remarks: Patent Analysis
Figure 17.7  Concluding Remarks: Market Forecast

List Of Tables

Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody-based Cancer Therapeutics
Table 3.3 Retroviral Vectors: Salient Features
Table 3.4 Lentiviral Vectors: Salient Features
Table 3.5 CAR-T Cell and TCR-based Therapies: Key Differences
Table 4.1 TCR-based Therapies: Clinical Pipeline
Table 4.2 TCR-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 4.3 TCR-based Therapies: Preclinical Pipeline
Table 4.4 List of TCR-based Developers 
Table 8.1 TCR-based Cell Therapies: List of Therapies Profiled
Table 8.2 Therapy Profile: Kimmtrak (Immunocore)
Table 8.3 Kimmtrak: Clinical Trial Information
Table 8.4 Kimmtrak: Clinical Trial Endpoints
Table 8.5 Kimmtrak: Clinical Trial Results
Table 8.6 Therapy Profile: GSK3377794 (GlaxoSmithKline)
Table 8.7 GSK3377794: Clinical Trial Information
Table 8.8 GSK3377794: Clinical Trial Endpoints
Table 8.9 GSK3377794: Clinical Trial Results
Table 8.10 Therapy Profile: ADP-A2M4 (Adaptimmune Therapeutics)
Table 8.11 ADP-A2M4: Clinical Trial Information
Table 8.12 ADP-A2M4: Clinical Trial Endpoints
Table 8.13 ADP-A2M4: Clinical Trial Results
Table 8.14 Therapy Profile: JTCR016 (Juno Therapeutics (Bristol Myers Squibb))
Table 8.15 JTCR016: Clinical Trial Information
Table 8.16 JTCR016: Clinical Trial Endpoints
Table 8.17 Therapy Profile: TBI-1301 (Takara Bio)
Table 8.18 TBI-1301: Clinical Trial Information
Table 8.19 TBI-1301: Clinical Trial Endpoints
Table 8.20 TBI-1301: Clinical Trial Results
Table 8.21 Therapy Profile: MDG108 (Medigene)
Table 8.22 MDG108: Clinical Trial Information
Table 8.23 MDG108: Clinical Trial Endpoints
Table 8.24 MDG108: Clinical Trial Results
Table 9.1 List of Partnerships and Collaborations, 2005-2022
Table 10.1 List of Funding and Investments, 2007-2022
Table 10.2 Funding and Investment Analysis: Summary of Investments
Table 11.1 Patent Analysis: Prominent CPC Symbols
Table 11.2 Patent Analysis: Most Popular CPC Symbols
Table 11.3 Patent Analysis: List of Top CPC Symbols
Table 11.4 Patent Analysis: Summary of Benchmarking Analysis
Table 11.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.1 Assessment Strategies for Different Manufacturing Processes
Table 12.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 12.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers 
Table 13.1 Price of Marketed Gene / Cell Therapies
Table 13.2 Price of Marketed Targeted Drugs
Table 13.3 TCR-based Therapies: Expert Opinions on Pricing
Table 13.4 TCR-based Therapies: Reimbursement Landscape
Table 14.1 TCR-based Therapies: List of Forecasted Molecules
Table 14.2 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore): Net Present Value (USD Million)
Table 14.3 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore): Value Creation Analysis (USD Million)
Table 14.4 GSK3377794 (GlaxoSmithKline): Net Present Value (USD Million)
Table 14.5 GSK3377794 (GlaxoSmithKline): Value Creation Analysis (USD Million)
Table 14.6 YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 14.7 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 14.8 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Net Present Value (USD Million)
Table 14.9 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Value Creation Analysis (USD Million)
Table 14.10 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Net Present Value (USD Million)
Table 14.11 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 14.12 NTLA-5001 (Intellia Therapeutics): Net Present Value (USD Million)
Table 14.13 NTLA-5001 (Intellia Therapeutics): Value Creation Analysis (USD Million)
Table 14.14 TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 14.15 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 14.16 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Net Present Value (USD Million)
Table 14.17 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
Table 14.18 FH-MCVA2TCR (TCRCure Biopharma): Net Present Value (USD Million)
Table 14.19 FH-MCVA2TCR (TCRCure Biopharma): Value Creation Analysis (USD Million) 
Table 15.1 Kimmtrak®: Drug Overview
Table 16.1 Leading TCR-based Therapy Developers
Table 16.2 Adaptimmune Therapeutics: Company Profile
Table 16.3 Alaunos Therapeutics: Company Profile
Table 16.4 Bristol Myers Squibb: Company Profile
Table 16.5 Cellular Biomedicine Group: Company Profile
Table 16.6 Gilead Sciences: Company Profile
Table 16.7 GlaxoSmithKline: Company Profile
Table 16.8 Immatics: Company Profile
Table 16.9 Immunocore: Company Profile
Table 16.10 Lion TCR: Company Profile
Table 16.11 Takara Bio: Company Profile
Table 16.12 Zelluna Immunotherapy: Company Profile
Table 19.1 TCR-based Therapies: Distribution by Type of Developer
Table 19.2 TCR-based Therapies: Distribution by Phase of Development
Table 19.3 TCR-based Therapies: Distribution by Therapeutic Area
Table 19.4 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Table 19.5 TCR-based Therapies: Distribution by Key Target Indications
Table 19.6 TCR-based Therapies: Distribution by Key Target Antigens
Table 19.7 TCR-based Therapies: Distribution by Source of T-Cells
Table 19.8 TCR-based Therapies: Distribution by Phase of Development and Source of T-Cells
Table 19.9 TCR-based Therapies: Distribution by Route of Administration
Table 19.10  TCR-based Therapies: Distribution by Dosing Frequency
Table 19.11  TCR-based Therapies: Distribution by Target Patient Segment
Table 19.12  TCR-based Therapies: Distribution by Type of Therapy
Table 19.13  Most Active Industry Players: Analysis by Number of TCR-based Therapies
Table 19.14  Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Table 19.15  TCR-based Therapy Developers: Distribution by Year of Establishment
Table 19.16  TCR-based Therapy Developers: Distribution by Company Size
Table 19.17  TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 19.18  TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 19.19  Clinical Trial Analysis: Cumulative Distribution of Trials by Trial Registration Year, Pre-2013-2022
Table 19.20  Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year, Pre-2013-2022
Table 19.21  Clinical Trial Analysis: Distribution by Trial Status
Table 19.22 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 19.23 Clinical Trial Analysis: Distribution of Trials by Trial Phase
Table 19.24 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 19.25 Clinical Trial Analysis: Distribution by Target Patient Segment
Table 19.26 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 19.27 Clinical Trial Analysis: Distribution by Study Design
Table 19.28 Most Active Industry Players: Distribution by Number of Registered Trials
Table 19.29  Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 19.30  Clinical Trial Analysis: Distribution of Trials by Geography
Table 19.31 Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 19.32 Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 19.33 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 19.34 KOL Analysis: Distribution by Type of Organization
Table 19.35 KOL Analysis: Distribution by Affiliated Organization
Table 19.36 KOL Analysis: Distribution by Qualification
Table 19.37 KOL Analysis: Distribution by Geography
Table 19.38 Most Prominent KOLs: Distribution by RA Score
Table 19.39 Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 19.40  Kimmtrak®: Estimated Sales Revenues
Table 19.41 GSK3377794: Estimated Sales Revenues
Table 19.42 ADP-A2M4: Estimated Sales Revenues
Table 19.43 JTCR016: Estimated Sales Revenues
Table 19.44 TBI-1301: Estimated Sales Revenues
Table 19.45 MDG1011: Estimated Sales Revenues 
Table 19.46 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 19.47 Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.48 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and Post-2015
Table 19.49 Partnerships and Collaborations: Distribution by Type of Partner
Table 19.50 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner, Pre-2015-2022
Table 19.51 Most Popular Products: Distribution by Number of Partnerships
Table 19.52 Most Active Industry Players: Distribution by Number of Partnerships
Table 19.53 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 19.54 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 19.55 Partnerships and Collaborations: Distribution of International and Local Deals
Table 19.56 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Table 19.57 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Table 19.58 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 19.59 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 19.60 Funding and Investment Analysis: Distribution by Type of Investor
Table 19.61 Funding and Investment Analysis: Distribution of Amount Invested by Type of Investor (USD Million)
Table 19.62 Most Active Players: Distribution by Number of Instances
Table 19.63 Most Active Players: Distribution by Amount Invested (USD Million)
Table 19.64 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 19.65 Patent Analysis: Distribution by Type of Patent
Table 19.66 Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 19.67 Patent Analysis: Cumulative Distribution Patent Application Year
Table 19.68 Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 19.69 Patent Analysis: Cumulative Year-wise Distribution of Filed Patent Applications
Table 19.70 Patent Analysis: Year-wise Distribution of Granted Patents and Patent Applications
Table 19.71 Patent Analysis: Distribution by Geography
Table 19.72 Patent Analysis: Distribution by Type of Player
Table 19.73 Patent Analysis: Distribution by CPC Symbols
Table 19.74 Leading Industry Players: Distribution by Number of Patents
Table 19.75 Leading Non-Industry Players: Distribution by Number of Patents
Table 19.76 Leading Patent Assignees: Distribution by Number of Patents
Table 19.77 Patent Analysis: Distribution by Patent Age
Table 19.78 TCR-based Therapies: Patent Valuation Analysis

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. 2seventy bio
  2. 6 Dimensions Capital
  3. A*STAR’s Genome Institute of Singapore
  4. AbVitro
  5. Actinium Pharmaceuticals
  6. Adaptimmune Therapeutics
  7. Adicet Bio
  8. AgonOx
  9. Alaunos Therapeutics
  10. Albert Einstein College of Medicine
  11. Alexandria Real Estate Equities
  12. Alex's Lemonade Stand Foundation
  13. Alpine Immune Sciences
  14. Altor BioScience
  15. Amgen
  16. Anocca
  17. Apdn Bvi
  18. Arbor Biotechnologies
  19. Astellas Pharma
  20. AstraZeneca
  21. Asymptote
  22. Athenex
  23. Atreca
  24. Autolus
  25. Axis Therapeutics
  26. Baylor College of Medicine
  27. Be The Match BioTherapies
  28. Beijing 302 Hospital
  29. Bellicum Pharmaceuticals
  30. Berlin Institute for Health
  31. Biocopy
  32. BioNTech
  33. bluebird bio
  34. Bristol Myers Squibb
  35. Broad Institute
  36. California Institute of Technology
  37. Cancer Institute and Hospital
  38. Cancer Research Technology
  39. Cardiff University
  40. Celgene
  41. Cell and Gene Therapy Catapult
  42. Cell Design Labs
  43. Cell Medica
  44. Cellares
  45. Cellular Biomedicine
  46. Cellular Therapeitics
  47. Cellular Therapeutics
  48. Changhai Hospital
  49. Charite-University Medicine Berlin
  50. China Immunotech (Beijing) Biotechnology
  51. Chinese PLA General Hospital
  52. Coolsingel Foundation
  53. Corregene Biotechnology
  54. Cryoport
  55. CTM CRC
  56. Cytovant Sciences
  57. Dana Farber Cancer Institute
  58. Duke-NUS Medical School
  59. Dutch Cancer Society
  60. Earle A. Chiles Research Institute
  61. Editas Medicine
  62. Ehime University
  63. Eli Lilly
  64. Erasmus Medical Center
  65. Etcembly
  66. Eutilex
  67. First Affiliated Hospital of Jinan University
  68. Fiverings
  69. Fosun Pharmaceutical
  70. Fred Hutchinson Cancer Research Center
  71. Fudan University
  72. Fujian Cancer Hospital
  73. Fujita Health University
  74. Gadeta
  75. GE Global Research
  76. GE Healthcare
  77. Genentech
  78. Genezen
  79. Genmab
  80. GigaGen
  81. Gilead Sciences
  82. GlaxoSmith Kline
  83. Glycostem Therapeutics
  84. Gritstone Oncology
  85. Guangdong Xiangxue Precision Medical Technology
  86. Guangzhou FineImmune Biotechnology
  87. Guangzhou Institute of Respiratory Disease
  88. Hebei Yanda Ludaopei Hospital
  89. Helmholtz Zentrum Munich
  90. Henan Provincial People's Hospital
  91. HiFiBiO Therapeutics
  92. Howard Hughes Medical Institute
  93. Immatics
  94. Immunocore
  95. Immunotech Biopharma
  96. Imperial Innovations
  97. Intellia Therapeutics
  98. Intrexon Corporation
  99. IRICoR
  100. Janssen
  101. Jonsson Comprehensive Cancer Center
  102. Juno Therapeutics
  103. JW Therapeutics
  104. Karolinska Institute
  105. KBI Pharma
  106. Kite Pharma (a Gilead Sciences Company)
  107. Legend Biotech
  108. Leiden University Medical Center
  109. Life Technologies
  110. Lion TCR
  111. Longwood Fund
  112. Lonza
  113. Loyola University
  114. Ludwig Cancer Research
  115. Lyell Immunopharma
  116. Marker Therapeutics
  117. Massachusetts General Hospital
  118. MaSTherCell
  119. Max Delbrück Center for Molecular Medicine 
  120. MaxCyte
  121. MD Anderson Cancer Center
  122. MediGene 
  123. MedImmune
  124. Memorial Sloan Kettering Cancer Center
  125. Merck
  126. Mie University
  127. Miltenyi Biotec
  128. Nagoya University
  129. NantKwest
  130. National Cancer Institute
  131. National Heart, Lung and Blood Institute
  132. National Institutes of Health
  133. National Institutes of Health Clinical Center (CC)
  134. Neogene Therapeutics
  135. Noile-Immune Biotech
  136. Novartis
  137. Novartis Venture Fund
  138. Oslo University Hospital
  139. Ospedale Pediatrico Bambino Gesù (OPBG)
  140. Otsuka Pharmaceutical
  141. Oxford BioMedica
  142. PACT Pharma
  143. Peking University
  144. PharmaEssentia
  145. Poseida Therapeutics
  146. Precigen
  147. Precision BioSciences
  148. Progenitor Cell Therapy
  149. Providence Cancer Center
  150. Providence Health & Services
  151. QIAGEN
  152. RA Capital Management
  153. Redmile Group
  154. RedoxTherapeis
  155. Regeneron
  156. Regeneron Pharma
  157. Roche
  158. Roswell Park Cancer Institute
  159. Rutgers University
  160. RXi Pharmaceuticals
  161. SciLifeLab
  162. Seattle Children’s Research Institute
  163. Seattle Genetics
  164. Second Affiliated Hospital of Guangzhou Medical University
  165. Selexis
  166. Shanghai Zhongshan Hospital
  167. Shenzhen BinDeBio
  168. Shenzhen Institute for Innovation and Translational Medicine
  169. Shenzhen Second People's Hospital
  170. Shionogi
  171. SignalOne Bio
  172. Simcere
  173. Stage Cell Therapeutics
  174. Statcom
  175. Structured Immunity
  176. Sun Yat-sen University
  177. Syracuse Biopharma
  178. Tactiva Therapeutics
  179. Takara Bio
  180. T-Cell Factory
  181. TCR Biotherapeutics
  182. TCR2 Therapeutics
  183. TCRCure Biopharma
  184. TCRyption
  185. T-Cure Bioscience
  186. TeneoBio
  187. The First Affiliated Hospital of Guangzhou Medical University
  188. The Leukemia & Lymphoma Society
  189. The Netherlands Cancer Institute
  190. The University of California
  191. The University of Texas Health Science Center
  192. The University of Texas MD Anderson Cancer Center
  193. Thermo Fisher Scientific
  194. Tianjin Medical University
  195. TILT Biotherapeutics
  196. T-knife Therapeutics
  197. Tmunity Therapeutics
  198. Treadwell Therapeutics
  199. Triumvira Immunologics
  200. Tscan Therapeutics
  201. Twist Bioscience
  202. Universal Cells
  203. University College London
  204. University Health Network
  205. University Medical Center Utrecht
  206. University of California
  207. University of California San Francisco
  208. University of Chicago
  209. University of Connecticut
  210. University of Lausanne
  211. University of Montreal
  212. University of Pennsylvania
  213. University of Southern California
  214. University of Tokyo Hospital
  215. University of Virginia Patent Foundation
  216. Unum Therapeutics
  217. US Health
  218. venBio
  219. Vineti
  220. Wellington Management
  221. Woodford Investment Management
  222. WuXi AppTec
  223. X-Body
  224. Xiangxue Life Sciences
  225. Xiangxue Pharmaceutical
  226. Xinqiao Hospital of Chongqing
  227. Zelluna Immunotherapy
  228. Zhejiang Huahai Pharmaceutical
  229. Zhejiang University
  230. Zhujiang Hospital
  231. ZIOPHARM Oncology

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com